You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
"Best Provider" Winner,
2019 Waters Rankings Awards:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Hangzhou Just Biotherapeutics closes $57M financing
Banking Essentials Newsletter December Edition Part 2
Banking Essentials Newsletter - November Edition
University Essentials | COVID-19 Economic Outlook in Banking: Rates and Long-Term Expectations: Q&A with the Experts
Estimating Credit Losses Under COVID-19 and the Post-Crisis Recovery
Hangzhou Just Biotherapeutics Ltd. closed a $57 million series B financing led by Temasek Holdings (Pte) Ltd. (Unspecified Vehicle) and existing investors Lilly Asia Ventures and ARCH Venture Partners LLC.
New investors in the round included Taikang, Hangzhou Economic & Technological Development Area, Bank of China and Bank of Hangzhou.
The funds will be used to advance the company's product pipeline and to complete a research and manufacturing facility in China.